biostudies-literatureLiu WTianjin Municipal Science and Technology Plan Programthe Distinguished Young Scholars of TianjinCAMS Innovation Fund for Medical SciencesNational Nature Science Foundation of Chinathe Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciencese008857https://www.ebi.ac.uk/biostudies/studies/S-EPMC11029269biostudies-literatureUnknown12(4)<h4>Background</h4>Approximately two-thirds of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) do not respond to or relapse after anti-CD19 chimeric antigen receptor T (CAR T)-cell therapy, leading to poor outcomes. Previous studies have suggested that intensified lymphodepletion and hematological stem cell infusion can promote adoptively transferred T-cell expansion, enhancing antitumor effects. Therefore, we conducted a phase I/II clinical trial in which CNCT19 (an anti-CD19 CAR T-cell) was administered after myeloablative high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) in patients with R/R LBCL.<h4>Methods</h4>Transplant-eligible patients with LBCL who were refractory to first-line immunochemotherapy or experiencing R/R status after salvaJournal for immunotherapy of cancerCombinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.PMC1102926922JCJQJC00070821019332022-I2M-1-0222020-I2M-C&amp;T-B-0852021-RC310-01122ZYCGSY008302021-I2M-1-0412022-I2M-C&amp;T-B-0892022-RC320-01Zou HLiu HDeng SChen LYi SMa YWang HZheng WZou DWang JWang KXiong WLiu WShi YQiu LLv LPeng GHuang WSui WLv RWang YWei JXu YfalseCombinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.<h4>Background</h4>Approximately two-thirds of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) do not respond to or relapse after anti-CD19 chimeric antigen receptor T (CAR T)-cell therapy, leading to poor outcomes. Previous studies have suggested that intensified lymphodepletion and hematological stem cell infusion can promote adoptively transferred T-cell expansion, enhancing antitumor effects. Therefore, we conducted a phase I/II clinical trial in which CNCT19 (an anti-CD19 CAR T-cell) was administered after myeloablative high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) in patients with R/R LBCL.<h4>Methods</h4>Transplant-eligible patients with LBCL who were refractory to first-line immunochemotherapy or experiencing R/R status after salva2024-01-01T00:00:00Z2024 Apr2026-06-08T06:02:10.947Z2026-06-08T03:14:14.113ZS-EPMC110292693863171210.1136/jitc-2024-008857